New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 26, 2013
16:11 EDTENDP, ABT, TEVA, COV, ACTFDA panel recommends new restrictions on painkiller, WSJ says
After two days of testimony, an FDA drug safety advisory panel voted 19-10 to recommended new restrictions on products containing hydrocodone—a category that includes Vicodin--should be reclassified as Schedule II controlled substances, along with other narcotic painkillers such as oxycodone, says the Wall Steet Journal. Hydrocodone products are currently in Schedule III. Reference Link
News For ACT;TEVA;ENDP;COV;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 14, 2015
08:35 EDTTEVATeva says data present case for TEV-48125 progression to Phase III
Subscribe for More Information
07:44 EDTTEVAInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
May 13, 2015
16:39 EDTACTAdamas Pharmaceuticals sees Namzaric launching in coming months
During its Q1 earnings report, Adamas (ADMS) stated, "In the coming months, we look forward to expanding our wholly-owned product pipeline with the initiation of a phase 2 clinical trial of ADS-5102 for a second CNS-related indication, completing enrollment in one of two ongoing phase 3 trials assessing ADS-5102 for the treatment of LID, and the U.S. launch of Namzaric by our collaborator, Actavis (ACT)."
08:02 EDTTEVAANI Pharmaceuticals acquires rights to testosterone gel 1%
Subscribe for More Information
May 11, 2015
14:27 EDTTEVACowen recommends adding to both Teva and Mylan at current levels
Cowen recommends adding to both Teva (TEVA) and Mylan (MYL) at current levels. The firm continues to believe that a Mylan transaction will proceed despite some early contentious language, and all of Mylan's concerns will be resolved.
12:51 EDTACTOn The Fly: Top stock stories at midday
Subscribe for More Information
11:53 EDTTEVATeva rejected chance to acquire Perrigo a few months ago, Globes reports
Subscribe for More Information
10:30 EDTABTAbbott names Brian Yoor as SVP, Finance and CFO
Subscribe for More Information
09:21 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTACTActavis says committed to utilizing FCF to accelerate debt repayment
Subscribe for More Information
08:57 EDTACTActavis says 'doing exceptionally well' on cost synergy capture
Subscribe for More Information
08:52 EDTACTActavis sets 'aspirational' FY17 EPS target of $25
Subscribe for More Information
08:48 EDTACTActavis sees sNDA submission for low dosage Linzess in 2016
Subscribe for More Information
07:34 EDTENDPEndo acquires portfolio of branded and generic products from Aspen Holdings
Subscribe for More Information
07:13 EDTENDPEndo raises FY15 adjusted EPS to $4.40-$4.60 from $4.35-$4.55, consensus $4.48
Sees FY15 revenue $2.9B-$3B, consensus $2.99B. Sees FY15 adjusted gross margin of between 64%-65%. Sees FY15 effective tax rate of 13%-14%.
07:12 EDTENDPEndo reports Q1 US Branded Pharmaceuticals revenue $285M
Reports Q1 US Generic Pharmaceuticals revenue $357M. Reports Q1 International Pharmaceuticals revenue $73M.
07:11 EDTENDPEndo reports Q1 adjusted EPS $1.17, consensus $1.06
Subscribe for More Information
06:40 EDTACTActavis sees Eluxadoline, Cariprazine PDUFAs in Q2
Subscribe for More Information
06:37 EDTACTActavis sees 2015 EPS $17.00-$18.50, consensus $17.70
Sees 2015 pro forma revenue $22M-$22.5B, consensus $21.47B. Sees 2015 total net revenue $20.5B-$21B.
06:35 EDTACTActavis reports Q1 EPS $4.30, consensus $3.94
Reports Q1 revenue $4.23B., consensus $4.03B. Reports adjusted EBITDA of $1.78B compared to $860M last year. Results include the contribution from Allergan businesses for the period following the close on March 17.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use